MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · New England Journal of Medicine · 2018 · 3.3K citations · Full text

Comprehensive genomic profiles of small cell lung cancer

Julie George, Jing Lim, Se Jin Jang et al. · Nature · 2015 · 2.3K citations · Full text

Cancer Genomics, Bronchial Neoplasm, Comprehensive Genomic Profiles +3

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Martin Peifer, Lynnette Fernandez‐Cuesta, Martin L. Sos et al. · Nature Genetics · 2012 · 1.4K citations · Full text

Engineering, Somatic Variant, Tumor Heterogeneity +10

Targeting MYC dependence in cancer by inhibiting BET bromodomains

Jennifer A. Mertz, Andrew R. Conery, Barbara M. Bryant et al. · Proceedings of the National Academy of Sciences · 2011 · 1.1K citations · Full text

Myc Transcript, Chromatin, Transcriptional Regulation +15